Repository logo
 

Cerebrospinal Fluid Cytokines and Neurodegeneration-Associated Proteins in Parkinson's Disease.

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Change log

Abstract

INTRODUCTION: Immune markers are altered in Parkinson's disease (PD), but relationships between cerebrospinal fluid (CSF) and plasma cytokines and associations with neurodegeneration-associated proteins remain unclear. METHODS: CSF and plasma samples and demographic/clinical measures were obtained from 35 PD patients. CSF samples were analyzed for cytokines (together with plasma) and for α-synuclein, amyloid β(1-42) peptide, total tau, and phospho(Thr231)-tau. RESULTS: There were no CSF-plasma cytokine correlations. Interleukin (IL)-8 was higher and interferon-γ, IL-10, and tumor necrosis factor-α were lower in CSF versus plasma. In CSF, total tau correlated positively with IL-8 and IL-1β, whereas α-synuclein correlated positively with amyloid β(1-42) and negatively with semantic fluency (a known marker of PD dementia risk). DISCUSSION: CSF and peripheral cytokine profiles in PD are not closely related. Associations between CSF IL-8 and IL-1β and tau suggest that CSF inflammatory changes may relate to tau pathology within PD. CSF α-synuclein/amyloid β may reflect the risk of developing PD dementia. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Description

Journal Title

Mov Disord

Conference Name

Journal ISSN

0885-3185
1531-8257

Volume Title

35

Publisher

Wiley

Rights and licensing

Except where otherwised noted, this item's license is described as All rights reserved
Sponsorship
Addenbrooke's Charitable Trust (ACT) (9968 MINUTE NO 24/14B)
Addenbrooke's Charitable Trust (ACT) (PF15/CWG)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
Medical Research Council (MR/R007446/1)
Medical Research Council (MC_PC_12009)
Medical Research Council (MC_PC_17230)
European Commission (242003)
Wellcome Trust (203151/Z/16/Z)
Funding for this work was provided by the Rosetrees Trust (M369-F1), Addenbrooke’s Charitable Trust (PF15/CWG) and the NIHR Cambridge Biomedical Research Centre Dementia and Neurodegeneration Theme (146281). RSW was supported by a Fellowship from Addenbrooke’s Charitable Trust (RG77199). SFM was supported by the Transeuro EU FP7 grant (242003) and is now an NIHR Academic Clinical Fellow (ACF-2015-23-501). DPB is supported by a Wellcome Trust Clinical Research Career Development Fellowship. RAB is an NIHR Senior Investigator (NF-SI-0616-10011) and is supported by the Wellcome Trust-MRC Cambridge Stem Cell Institute. CHWG holds a RCUK/UKRI Research Innovation Fellowship awarded by the Medical Research Council (MR/R007446/1) and receives support from the Cambridge Centre for Parkinson-Plus.